Deprenyl decreases an endogenous parkinsonism-inducing compound, 1-benzyl-1,2,3,4-tetrahydroisoquinoline in mice: in vivo and in vitro studies.
We examined the effect of deprenyl, a promising drug for the therapy of Parkinson's disease on the formation of a parkinsonism-inducing compound, 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1BnTIQ). The 1BnTIQ content was significantly decreased in the brain of deprenyl-treated mouse in vivo, and deprenyl also inhibited 1BnTIQ formation from phenethylamine by a mouse brain homogenate supernatant in vitro. In vivo, the content of a parkinsonism-preventing compound, 1-methyl-1,2,3, 4-tetrahydroisoquinoline (1MeTIQ) was slightly increased in mice injected with deprenyl. The marked decrease of the ratio of 1BnTIQ to 1MeTIQ might play a role in the clinical effect of deprenyl.
Kotake
Y
Y
Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo 113, Japan.
Tasaki
Y
Y
Hirobe
M
M
Ohta
S
S
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000378:metabolism*; D001923:Brain Chemistry / Q000187:drug effects*; D002849:Chromatography, Gas; D003864:Depression, Chemical; D066298:In Vitro Techniques; D007546:Isoquinolines / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D010302:Parkinson Disease, Secondary / Q000378:metabolism*; D010627:Phenethylamines / Q000378:metabolism; D012642:Selegiline / Q000494:pharmacology*; D044005:Tetrahydroisoquinolines
D000889:Anti-Arrhythmia Agents; D007546:Isoquinolines; D008996:Monoamine Oxidase Inhibitors; D010627:Phenethylamines; D044005:Tetrahydroisoquinolines; D012642:Selegiline; C084924:1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline